Evaluation of Response of Dasatinib to Treat Mastocytosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00979160|
Recruitment Status : Unknown
Verified September 2009 by Federico II University.
Recruitment status was: Not yet recruiting
First Posted : September 17, 2009
Last Update Posted : September 18, 2009
This is a multicenter, open-label, single arm phase II non-randomized study of dasatinib in which subjects with systemic mastocytosis (SM) will be treated with a continuous regimen of dasatinib.
Upon completion of a treatment induction period, subjects will be treated with dasatinib at a dose of 100 mg per os (OS) once daily (QD).
|Condition or disease||Intervention/treatment||Phase|
|Systemic Mastocytosis||Drug: Dasatinib||Phase 2|
Dasatinib may have clinical efficacy and is safe in subjects with SM. This Multicenter, open-label, single arm Phase II study will investigate the clinical response rate in terms of both B/C findings and mediator-related symptoms.
30 adult patients will be treated with a continuous regimen of dasatinib at a starting dose of 20 mg administered orally (PO) once daily (QD), that can be escalated up to 100 mg QD at the end of Week 3. Upon completion of a treatment induction period, subjects will be treated with dasatinib at a daily dose of 100 mg PO QD. Patients will remain on dasatinib treatment for 12 months unless disease progression, unacceptable toxicity or other reasons determine treatment discontinuation. Subjects may continue receiving protocol therapy as long as they are deriving a clinical benefit.
Additionally, all subjects will be followed until disease progression, death, or 12 months beyond discontinuation from study treatment.
The total duration of the study is estimated to 36 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Multicenter, Open-Label, Single Arm Phase II Clinical Trial of Dasatinib in the Treatment of Systemic Mastocytosis|
|Study Start Date :||November 2009|
|Estimated Primary Completion Date :||December 2011|
|Estimated Study Completion Date :||December 2012|
Patient will be treat at a starting dose of 20mg once daily, that can be escalated up to 100mg once daily.
Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient will remain on treatment for 12 months.
Other Name: BMS-354825-03
- To assess the clinical response rate in terms of both B/C findings and mediator-related symptoms in subjects with SM who have been treated with dasatinib. [ Time Frame: December 2011 ]
- To assess of the Time to Response (TTR), Duration of Response (DOR) and Progression-Free survival (PFS). [ Time Frame: December 2012 ]
- To evaluate the changes in specific biological markers and molecular mutations. [ Time Frame: June 2012 ]
- To evaluate the safety and toxicity of dasatinib in this population. [ Time Frame: December 2011 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00979160
|Contact: Massimo Triggiani, email@example.com|
|Istituto di ematologia "L e A Seragnoli" - Policlinico universitario Sant'Orsola-Malpighi||Not yet recruiting|
|Bologna, Italy, 40138|
|Contact: Giovanni Martinelli, MD +39516363680 firstname.lastname@example.org|
|Contact: Barbara Lama, MD +390516363827 email@example.com|
|Sub-Investigator: Stefania Paolini, MD|
|Dipartimento di Ematologia - S.O.D. di Ematologia Università degli Studi di Firenze - Azienda Ospedaliera Careggi||Not yet recruiting|
|Firenze, Italy, 50134|
|Contact: Alessandro Vannucchi, MD +39 0557947688 firstname.lastname@example.org|
|Sub-Investigator: Lisa Pieri, MD|
|Divisione di Ematologia Ospedale Niguarda Ca' Grande||Not yet recruiting|
|Milano, Italy, 20162|
|Contact: Roberto Cairoli, MD +39 02 64442668 email@example.com|
|Divisione di Allergologia e Immunologia Clinica, Università Federico II||Not yet recruiting|
|Napoli, Italy, 80131|
|Contact: Massimo Triggiani, MD +390817462218 firstname.lastname@example.org|
|Sub-Investigator: Diomira Magliacane, MD|
|Divisione di Ematologia Università di Torino Ospedale San Luigi Gonzaga||Not yet recruiting|
|Orbassano (TO), Italy, 10043|
|Contact: Daniela Cilloni, MD +39 011 9026610 email@example.com|
|Sub-Investigator: Emanuela Messa, MD|
|Istituto di Ematologia Università degli Studi di Pavia - Policlinico S. Matteo IRCCS||Not yet recruiting|
|Pavia, Italy, 27100|
|Contact: Serena Merante, MD +39 0382 503082 firstname.lastname@example.org|
|Unità di Ematologia e Trapianto Osseo CROB, Centro di Riferimento Oncologico di Basilicata +39 0972 726729 Fax +30 0972 726217 e-mail: email@example.com||Not yet recruiting|
|Rionero in Vulture (Pz), Italy|
|Contact: Pellegrino Musto, MD +39 0972 726729 firstname.lastname@example.org|
|Ematologia Tor Vergata University Hospital||Not yet recruiting|
|Roma, Italy, 00133|
|Contact: Adriano Venditti, MD +39 06 20903219 email@example.com|
|Principal Investigator: Sergio Amadori, MD|
|Divisione di Ematologia Policlinico Universitario "Agostino Gemelli"|
|Roma, Italy, 00168|
|Ematologia e Trapianti Università degli Studi di Siena - Policlinico S. Maria alle Scotte||Not yet recruiting|
|Siena, Italy, 53100|
|Contact: Michela Rondoni, MD +39 0577 586798 firstname.lastname@example.org|
|Principal Investigator: Francesco Lauria, MD|
|Divisione di Ematologia e Trapianto Midollo Osseo Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia"||Not yet recruiting|
|Udine, Italy, 33100|
|Contact: Mario Tiribelli, MD +39 0432 55966 email@example.com|
|Principal Investigator: Renato Fanin, MD|
|Sezione di Ematologia - Dipartimento di Medicina Clinica e Sperimentale Policlinico G.B.Rossi - Università degli Studi di Verona||Not yet recruiting|
|Verona, Italy, 37134|
|Contact: Roberta Zanotti, MD +39 045 8074812 firstname.lastname@example.org|
|Principal Investigator:||Massimo Triggiani, MD||Università Federico II|